ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BHC vs IDYA // EV/EBITDA & P/E VALUATION

Bausch Health Companies Inc. (NYSE) VS. IDEAYA Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: BHC 7 — IDYA 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BHC VS. IDYA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BHC IDYA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 7.60% -13.80% +21.40 BHC /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 10.5x — — TIE /valuation <GO>
Free Cash Flow Yield 22.00% -2.31% +24.31 BHC /fcf-yield <GO>
Operating Margin 17.70% -60.00% +77.70 BHC /operating-margins <GO>
Net Profit Margin 1.50% -52.00% +53.50 BHC /net-margins <GO>
Revenue Growth (YoY) 6.70% 180.00% -173.30 IDYA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.45 21.49 -21.04 IDYA /balance-sheet <GO>
Piotroski F-Score Quality 9/9 4/9 +5.00 BHC /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 76.7 34.6 +42.14 BHC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.97 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 19.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.33B $3.17B $161.2M BHC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BHC REV IDYA REV BHC GROSS % IDYA GROSS % BHC FCF IDYA FCF
FY 2025 $10.27B $218.7M — — $1.00B -$73.5M
FY 2024 $9.63B $7.0M — — $1.26B -$251.4M
FY 2023 $8.76B $23.4M — — $637.9M -$115.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BHC // BETA 0.97
IDYA // BETA —